F-ara-A, an agent that inhibits DNA synthesis and is a cornerstone for the treatment for CLL patients [36] as well as AMD3100, a CXCR4 small molecule inhibitor [37], were evaluated for comparison. This evidence concerns the gene CXCR4 and B-cell chronic lymphocytic leukemia.